# OnCo record nct06166589 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06166589/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06166589", "NCT06166589" ;
  schema:name "Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer"@en ;
  schema:description "A phase 2 trial of zimberelimab, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1) and fOLFIRI (5-FU, leucovorin, irinotecan) in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06166589/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06166589> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/zimberelimab/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/drugs/folfiri/> .